LLY Soars 16% In A Single Month: How Does It Compare With Others?
Here is how Eli Lilly (LLY) stacks up against its peers in size, valuation, growth and margin.
- LLY has the highest operating margin among peers at 43.0%.
- LLY’s revenue growth of 36.8% in the last 12 months is strong, outpacing MRK, PFE, BMY, BDX.
- LLY’s stock is down 17.5% in last 1 year, and trades at a PE of 48.1; it underperformed PFE, BMY, BDX.
As a quick background, Eli Lilly provides innovative pharmaceuticals globally, including treatments for cancer, rheumatoid arthritis, and autoimmune diseases such as psoriasis and ankylosing spondylitis.
| LLY | MRK | PFE | BMY | BDX | |
|---|---|---|---|---|---|
| Market Cap ($ Bil) | 663.2 | 211.1 | 139.6 | 94.9 | 55.0 |
| Revenue ($ Bil) | 53.3 | 63.6 | 63.8 | 47.6 | 21.4 |
| PE Ratio | 48.1 | 12.9 | 13.0 | 17.5 | 34.7 |
| LTM Revenue Growth | 36.8% | 1.8% | 13.5% | 4.6% | 7.9% |
| LTM Operating Margin | 43.0% | 31.2% | 26.1% | 16.5% | 13.8% |
| LTM FCF Margin | -0.1% | 23.1% | 19.5% | 27.5% | 11.9% |
| 12M Market Return | -17.5% | -26.2% | -8.0% | -0.9% | -15.6% |
Why does this matter? LLY just went up 15.5% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell LLY Stock to see if Eli Lilly holds up as a quality investment.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
- Can Rivian’s Services Business 2x The Stock?
- How Broadcom Became The Most Indispensable Name In Tech
- The Nvidia Threat Masked Inside Cisco’s Results
- Catalysts That Could Propel Advanced Micro Devices Stock to the Moon
- 3 Forces That Could Shake Tesla Stock
- Could FactSet Research Systems Stock’s Cash Flow Spark the Next Rally?
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| LLY | 36.8% | 32.0% | 19.6% | 0.8% |
| MRK | 1.8% | 6.7% | 1.4% | 21.7% |
| PFE | 13.5% | 6.8% | -41.1% | 24.5% |
| BMY | 4.6% | 7.3% | -2.5% | -0.5% |
| BDX | 7.9% | 4.2% | 2.7% | -1.4% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| LLY | 43.0% | 38.9% | 31.6% | 30.3% |
| MRK | 31.2% | 31.5% | 4.9% | 30.8% |
| PFE | 26.1% | 23.5% | 7.4% | 37.7% |
| BMY | 16.5% | 12.2% | 18.2% | 19.7% |
| BDX | 13.8% | 14.2% | 12.5% | 13.1% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| LLY | 48.1 | 65.7 | 100.1 | 52.8 |
| MRK | 12.9 | 14.7 | 757.8 | 19.3 |
| PFE | 13.0 | 18.7 | 76.7 | 9.2 |
| BMY | 17.5 | -12.8 | 13.2 | 24.2 |
| BDX | 34.7 | 38.6 | 47.0 | 40.7 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.